Compare · CDRE vs EW
CDRE vs EW
Side-by-side comparison of Cadre Holdings Inc. (CDRE) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CDRE and EW operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $49.36B, about 39.7x CDRE ($1.24B).
- Over the past year, CDRE is down 9.9% and EW is up 11.9% - EW leads by 21.8 points.
- EW has hit the wire 6 times in the past 4 weeks while CDRE has been quiet.
- EW has more recent analyst coverage (25 ratings vs 12 for CDRE).
- Company
- Cadre Holdings Inc.
- Edwards Lifesciences Corporation
- Price
- $29.07-3.74%
- $85.70-2.46%
- Market cap
- $1.24B
- $49.36B
- 1M return
- +1.11%
- -3.25%
- 1Y return
- -9.89%
- +11.92%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 6
- Recent ratings
- 12
- 25
Cadre Holdings Inc.
Cadre Holdings, Inc. manufactures and distributes safety and survivability equipment that provides protection to users in hazardous or life-threatening situations. It primarily provides body armor product, such as concealable, corrections, and tactical armor under the Safariland and Protech Tactical brands; survival suits, remotely operated vehicles, specialty tools, blast sensors, accessories, and vehicle blast attenuation seats for bomb safety technicians; bomb suits; duty gear, including belts and accessories; and other protective and law enforcement equipment. The company also offers third-party products, such as uniforms, optics, boots, firearms, and ammunition. It serves first responders, such as state and local law enforcement, fire and rescue, explosive ordnance disposal technicians, emergency medical technicians, fishing, and wildlife enforcement and departments of corrections, as well as federal agencies including the U.S. Department of State, U.S. Department of Defense, U.S. Department of Interior, U.S. Department of Justice, U.S. Department of Homeland Security, U.S. Department of Corrections, and various foreign government agencies internationally. The company was incorporated in 2012 and is headquartered in Jacksonville, Florida.
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest CDRE
- CEO AND CHAIRMAN Kanders Warren B sold $2,068,000 worth of shares (75,000 units at $27.57) (SEC Form 4)
- SEC Form 4 filed by Director Kissel Mary E.
- SEC Form 4 filed by Director Quigley William G Iii
- Amendment: SEC Form SCHEDULE 13D/A filed by Cadre Holdings Inc.
- SEC Form 4 filed by Director Norton Hamish
- SEC Form 4 filed by Director Sokolow Nicolas
- SEC Form 4 filed by CHIEF FINANCIAL OFFICER Browers Blaine
- SEC Form 4 filed by PRESIDENT Williams Brad
- SEC Form 4 filed by CEO AND CHAIRMAN Kanders Warren B
- CEO AND CHAIRMAN Kanders Warren B sold $6,539,000 worth of shares (225,000 units at $29.06) (SEC Form 4)
Latest EW
- Edwards Lifesciences to Host Earnings Conference Call on July 23, 2026
- CVP, EMEACLA Bruls Annette covered exercise/tax liability with 109 shares, decreasing direct ownership by 0.53% to 20,628 units (SEC Form 4) (for withholding tax)
- CVP, Chief Financial Officer Mistras Theodora was granted 99,920 shares (SEC Form 4)
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,762 worth of shares (619 units at $91.70) as part of a pre-agreed trading plan (SEC Form 4)
- CVP, TAVR Lippis Daniel J. covered exercise/tax liability with 377 shares, decreasing direct ownership by 0.93% to 40,034 units (SEC Form 4) to cover taxes
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,577 worth of shares (619 units at $91.40) as part of a pre-agreed trading plan (SEC Form 4)
- Edwards’ Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves
- CEO Zovighian Bernard J sold $45,982 worth of shares (523 units at $87.92) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 11-K filed by Edwards Lifesciences Corporation
- SEC Form 11-K filed by Edwards Lifesciences Corporation